KMT2D regulates activation, localization, and integrin expression by T-cells.
Animals
Mice
Integrins
/ metabolism
Lymphocyte Activation
/ genetics
DNA-Binding Proteins
/ genetics
T-Lymphocytes
/ immunology
Mice, Knockout
Vestibular Diseases
/ genetics
Face
/ abnormalities
Humans
Histone-Lysine N-Methyltransferase
/ genetics
Mice, Inbred C57BL
Neoplasm Proteins
/ genetics
Signal Transduction
Gene Expression Regulation
Abnormalities, Multiple
Hematologic Diseases
Myeloid-Lymphoid Leukemia Protein
Itgal
Itgb7
KS1-associated immune deficiency (KSAID)
Kabuki syndrome (KS)
integrin switching
recent thymic emigrant (RTE)
thymocyte
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2024
2024
Historique:
received:
20
11
2023
accepted:
26
03
2024
medline:
20
5
2024
pubmed:
20
5
2024
entrez:
20
5
2024
Statut:
epublish
Résumé
Individuals with Kabuki syndrome present with immunodeficiency; however, how pathogenic variants in the gene encoding the histone-modifying enzyme lysine methyltransferase 2D (KMT2D) lead to immune alterations remain poorly understood. Following up on our prior report of KMT2D-altered integrin expression in B-cells, we performed targeted analyses of KMT2D's influence on integrin expression in T-cells throughout development (thymocytes through peripheral T-cells) in murine cells with constitutive- and conditional-targeted
Identifiants
pubmed: 38765012
doi: 10.3389/fimmu.2024.1341745
pmc: PMC11099208
doi:
Substances chimiques
Kmt2d protein, mouse
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1341745Informations de copyright
Copyright © 2024 Potter, Zhang, Kotliar, Wu, Schafer, Stefan, Boukas, Qu’d, Bodamer, Simpson, Barski, Lindsley and Bjornsson.
Déclaration de conflit d'intérêts
AB is a cofounder of Datirium, the developer of Scientific Data Analysis Platform https://SciDAP.com used here for processing RNA-Seq data. AB and MK developed CWL-Airflow licensed to Datirium, LLC. AL is an employee of Amgen Inc. HB is a consultant for Mahzi therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.